Market Overview

Regeneron Pharmaceuticals Spokesperson Declines Comment on Earlier Takeover Chatter

Related REGN
UPDATE: Morgan Stanley Reiterates On Regeneron Pharmaceuticals Following Good Results Of Drug Study
Benzinga's Top #PreMarket Gainers
Related SNY
Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield
UPDATE: Regeneron, Sanofi Offer Positive Results from Phase 2b Study of Dupilum, All Doses Met Primary Endpoint
Allergan Reportedly Seeks Alternate Suitor (Fox Business)

Regeneron (NASDAQ: REGN) spokesperson Peter Dworkin, while declining comment on earlier takeover chatter involving Sanofi (NYSE: SNY), did say that the two companies have a solid working relationship and have stated it would be advantageous to keep the relationship going as it is now, as separate companies.

Sanofi is Regeneron's largest shareholder currently. There is a standstill agreement in place preventing Sanofi from acquiring more than 30% of Regeneron's shares.

Regeneron shares spiked to a high of $145.81 on Thursday.

Posted-In: News Rumors M&A Movers

 

Most Popular

Related Articles (REGN + SNY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters